- Home
- JNVR vs EVAX Comparison
JNVR vs EVAX Comparison
Compare JNVR & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- EVAX
- Stock Information
- Founded
- JNVR 2018
- EVAX 2008
- Country
- JNVR United States
- EVAX Denmark
- Employees
- JNVR N/A
- EVAX N/A
- Industry
- JNVR Finance: Consumer Services
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JNVR Finance
- EVAX Health Care
- Exchange
- JNVR Nasdaq
- EVAX Nasdaq
- Market Cap
- JNVR 7.3M
- EVAX 8.7M
- IPO Year
- JNVR 2023
- EVAX 2021
- Fundamental
- Price
- JNVR $0.68
- EVAX $0.90
- Analyst Decision
- JNVR
- EVAX Strong Buy
- Analyst Count
- JNVR 0
- EVAX 2
- Target Price
- JNVR N/A
- EVAX $11.00
- AVG Volume (30 Days)
- JNVR 200.1K
- EVAX 82.5K
- Earning Date
- JNVR 11-06-2024
- EVAX 10-31-2024
- Dividend Yield
- JNVR N/A
- EVAX N/A
- EPS Growth
- JNVR N/A
- EVAX N/A
- EPS
- JNVR N/A
- EVAX N/A
- Revenue
- JNVR $1,820,969.00
- EVAX $3,295,000.00
- Revenue This Year
- JNVR N/A
- EVAX $4,845.21
- Revenue Next Year
- JNVR N/A
- EVAX $30.30
- P/E Ratio
- JNVR N/A
- EVAX N/A
- Revenue Growth
- JNVR N/A
- EVAX N/A
- 52 Week Low
- JNVR $0.42
- EVAX $0.85
- 52 Week High
- JNVR $1.48
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- JNVR 55.82
- EVAX 21.83
- Support Level
- JNVR $0.60
- EVAX $0.85
- Resistance Level
- JNVR $0.71
- EVAX $0.96
- Average True Range (ATR)
- JNVR 0.10
- EVAX 0.15
- MACD
- JNVR 0.00
- EVAX -0.00
- Stochastic Oscillator
- JNVR 48.36
- EVAX 5.75
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.